CyberKnife Stereotactic Radiotherapy as Monotherapy for Low- to Intermediate-Stage Prostate Cancer: Early Experience, Feasibility, and Tolerance
Authors:
- 1 May 2010
- journal article
- research article
- Published by SAGE Publications in Journal of Endourology
- Vol. 24 (5) , 865-869
Abstract
Purpose: The CyberKnife (CK), a linear accelerator mounted on a robotic device, enables excellent dose conformation to the target and minimizes dose to surrounding normal tissue. It is a very suitable device for performing hypofractionated stereotactic body radiotherapy as monotherapy for low- to intermediate-risk prostate cancer patients. We report our early experience using this technique. Materials and Methods: Between June 2008 and June 2009, 10 patients underwent CK monotherapy as treatment for their prostate cancer (stage ≤T2b, Gleason score (GS) ≤7, initial PSA ≤15 μg/L). The prescribed dose was 38 Gy in four daily fractions of 9.5 Gy. The International Prostate Symptom Score and Radiation Therapy Oncology Group symptom scale were prospectively administered before and at 0.5, 1, 2, 3, 6, and 12 months. Results: Median age of the patients was 71 years (range, 66–76). Three patients had stage T2a and 7a T1c disease, one patient had GS of 7, and all others had GS of 6. Median follow-up was 5.1 months. Median initial PSA was 8.3 ng/mL (range, 1.3–13.6 ng/mL). Median planning target volume delineated on computed tomography after matching with the magnetic resonance imaging scan was 107 cc (range, 42–158 cc). The median V100 of the prostate was 95.8% (range, 94.8–97.2). The D95 of the prostate was 38.3 Gy (range, 38.1–38.8 Gy). The constraints for the bladder, rectum, and urethra were well met. The International Prostate Symptom Scores after 3 months were stable compared with the pretreatment scores. Urinary and bowel Radiation Therapy Oncology Group symptoms were mild and within the expected levels. Conclusions: This regimen of stereotactic CK monotherapy for low- to intermediate-risk prostate cancer with excellent dose coverage of the prostate was well tolerated. Data collection is ongoing for further assessment of toxicity and PSA response.Keywords
This publication has 25 references indexed in Scilit:
- Late Outcomes Following Hypofractionated Conformal Radiotherapy vs. Standard Fractionation for Localized Prostate Cancer: A Nonrandomized Contemporary ComparisonInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- A Phase II Study of High-Dose-Rate Afterloading Brachytherapy as Monotherapy for the Treatment of Localized Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Balancing on a Knife's Edge: Evidence-Based Medicine and the Marketing of Health TechnologyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Virtual HDRSM CyberKnife Treatment for Localized Prostatic Carcinoma: Dosimetry Comparison With HDR Brachytherapy and Preliminary Clinical ObservationsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Guideline for the Management of Clinically Localized Prostate Cancer: 2007 UpdateJournal of Urology, 2007
- Efficacy of High Dose Per Fraction Radiation for Implanted Human Prostate Cancer in a Nude Mouse ModelJournal of Urology, 2006
- Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate CancerJournal of Clinical Oncology, 2005
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1991